SCHEDULE: Paradigm BioCapital Discloses 6.1% Stake in Maze Therapeutics

Paradigm BioCapital Advisors LP and related entities have reported a 6.1% beneficial ownership stake in Maze Therapeutics, Inc. common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively beneficially own 3,051,087 shares of Maze Therapeutics, Inc. Common Stock.
• This represents 6.1% of the total outstanding shares of Maze Therapeutics, Inc.
• Paradigm BioCapital International Fund Ltd. beneficially owns 2,688,520 shares, representing 5.4% of the class.
• The percentages are based on 49,708,658 shares of Common Stock outstanding as of March 20, 2026, as reported by Maze Therapeutics, Inc. in its Form 10-K.
• The filing is a Schedule 13G, indicating a passive investment intent, with the reporting persons certifying that the securities were not acquired to change or influence control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant passive stake by a specialized investment firm suggests confidence in Maze Therapeutics, though it doesn't imply active engagement in management or strategy.

Positives

• Significant institutional investment from Paradigm BioCapital, signaling confidence in Maze Therapeutics' prospects.
• Paradigm BioCapital Advisors LP is an investment adviser, suggesting a professionally managed investment decision.

Risks

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating the risk of activist investor intervention.

Future Outlook

The filing is a Schedule 13G, which is a disclosure of passive ownership and does not typically contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future. The reporting persons certify they do not intend to change or influence control.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G often signal increased investor confidence or strategic positioning within the biotechnology sector. A significant stake by a specialized bio-capital firm like Paradigm BioCapital could indicate a positive long-term view on Maze Therapeutics' pipeline or market potential, aligning with broader trends of targeted investments in promising biotech ventures.

Comparison to Industry Standards

• A 6.1% stake is a substantial passive investment for a single institutional group, often seen as a strong vote of confidence in a company, particularly in the biotech sector where early-stage companies rely heavily on institutional backing.
• Compared to other biotech companies, a similar percentage ownership by a specialized fund like Paradigm BioCapital in companies such as Moderna (early stages) or BioNTech (pre-IPO) often preceded significant growth, though the specific context of Maze Therapeutics' pipeline and market position would require further analysis.

Stakeholder Impact

• Shareholders: May view the institutional investment as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: The passive nature of the investment means no immediate pressure for strategic changes, allowing management to focus on current plans.

Next Steps

• Maze Therapeutics, Inc. will continue its operations as an independent entity.
• Paradigm BioCapital and its affiliates will continue to hold their investment in Maze Therapeutics, Inc.

Key Dates

Recommendation

The disclosure of a significant passive stake by a reputable institutional investor like Paradigm BioCapital is generally a positive signal, indicating confidence in Maze Therapeutics. However, without additional information on the company's financial performance, strategic initiatives, or specific catalysts, a 'hold' recommendation is appropriate. This filing primarily confirms institutional interest rather than providing new operational or financial data that would warrant a 'buy' or 'sell' decision.

Keywords

Maze Therapeutics, Paradigm BioCapital, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Biotechnology, Healthcare